ClinicalTrials.gg
RecruitingNCT07423637Updated Oct 14, 2026

The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment

An interventional study of Omnipod 5 and Multiple daily injections of insulin in Type 1 Diabetes, sponsored by Helsinki University Central Hospital. Recruiting at 2 sites in Finland. Open to participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
7 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Diabetes Mellitus, Type 1 with a site in Finland — 8 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 1 · Finland.

Planned enrollment
41st of 53
100 · median 272
Started
2026
with 2 others
No phase
10 of 66
1 open now
Registered
66th of 66
by date
Lead sponsor
4 of 66
Helsinki University Central Hospital

Among the 66 studies in Diabetes Mellitus, Type 1 with a site in Finland, this one is the 41st largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 66th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 66 studies in Diabetes Mellitus, Type 1 with a site in Finland are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 7 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 1 with a site in Finland, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications and cost-effectiveness compared to multiple daily injections (MDI) and continuous glucose monitoring (CGM). The immediate costs of AID therapy are higher than costs of multiple daily injection therapy, and there has been debate whether the more expensive AID therapy is justified. No research on the cost-effectiveness of AID use in children has been conducted so far in Finland, and there is generally very little research data on the long-term treatment of type 1 diabetes with AID systems. AID therapy has been studied from the point of diagno-sis of type 1 diabetes in two centers (USA and the UK) but from the perspective of maintain-ing subject's own insulin secretion. A long-term randomized and controlled study on the out-comes and cost-effectiveness of AID therapy, started from diagnosis of diabetes, is essential to create evidence-based data for optimizing current treatment recommendations.

Our hypothesis is that AID treatment keeps the glycemic outcomes in targets in the long term and decreases diabetes distress. During longer time, AID system decreases the amount of micro- and macrovascular complications and is cost-effective treatment for children with type 1 diabetes (CwT1D).

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • type 1 diabetes
  • Automated insulin delivery system
04

Who can participate

Ages eligible
7 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents aged 7-15 years who are re-cently (within a month) diagnosed with type 1 diabetes at the Children's and Adolescents' Unit of HUH at the New Children's Hospital and Jorvi Hospital

Exclusion criteria

Exclusion Criteria:

  • Addison's disease
  • Renal failure
  • Untreated coeliac disease
  • Untreated thyroid disorder
  • Poorly controlled asthma, per investigator judgment.
  • Unresolved adverse skin conditions in the area of sensor placement (e.g. pso-riasis, rash, Staphylococcus infection).
  • Participating in an study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Early AID-treatment

    Automated insulin delivery system (Omnipod 5) is initiated after T1D diagnosis. Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries. Continious glucose monitoring (CGM) is used.

    Device: Omnipod 5

  • Active comparator
    Control group

    Multiple daily insulin injections (MDI) is initiated after T1D with a standard treatment protocol. Continious glucose monitoring (CGM) is used.

    Drug: Multiple daily injections of insulin

Interventions

  • DeviceOmnipod 5

    Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries

  • DrugMultiple daily injections of insulin

    Multiple daily infections of insulin to treat type 1 diabetes

06

What researchers measure

Primary outcomes

  1. Time in Range

    Percentage (%) of the time patients' glucose levels are within the target range based on continuous glucose monitoring (time in range =TIR, 3.9-10 mmol/l).

    Time frame: During the first 2 years

Secondary outcomes

  1. TINR

    Time spent (%) in normoglycemic range (TINR, 3.9-7.8 mmol/l) based on continuous glucose monitorin (CGM) data

    Time frame: During the first 2 years

  2. Complications

    The development of diabetes-related complications such as diabetic nephropathy, diabetic retinopathy, neuropathy, coronary artery disease

    Time frame: 15 years

  3. HbA1c

    The change in HbA1c levels (mmol/mol) during the treatment between the groups

    Time frame: 2 years

  4. Mean sensor glucose value

    The change in mean sensor glucose value (mmol/l) obtained from continuous glucose monitoring between the groups during treatment

    Time frame: 2 years

  5. Glycemic variability

    The change in glycemic variability (coefficient of variation CV (SD/mean sensor glucose x 100%)) obtained from continuous glucose monitoring data between the groups during treatment

    Time frame: 2 years

  6. Continuous Ketone monitoring (CKM)

    Continous Ketone monitoring with a CKM sensor will be performed at 2 time points during the follow-up period

    Time frame: During the first 2 years

  7. Cost-effectiveness

    The cost-effectiveness of different treatment modalities for T1D in children with Cost-Utility Analysis modeling

    Time frame: 15 years

  8. Custom food list

    The Custom Food List is a personalized menu integrated into the AID pump. Patients can select a predefined meal from the list before eating, without calculating the carbohydrate content, and the pump automatically delivers the preset insulin dose assigned to that item. We evaluated the impact of using the Custom Food List on Time in range (TIR, %), Time in Normoglycemic Range (TINR, %), Time below Range (TBR, %), and postprandial glucose levels compared with conventional carbohydrate counting.

    Time frame: During the first 2 years

07

Study locations

2 of 2 sites recruiting
  • Jorvi Hospital
    Espoo, 02740, Finland
    Recruiting
    • Anna-Kaisa Tuomaala, MD, PhD · Contactanna-kaisa.tuomaala@hus.fi · +358505430180
    • Mari-Anne Pulkkinen, MD,PhD · Contactmari-anne.pulkkinen@hus.fi · +358094711
    • Mari-Anne Pulkkinen, MD, PhD · Principal investigator
    • Anna-Kaisa Tuomaala, MD, PhD · Sub investigator
    • Tero Varimo, MD, PhD · Sub investigator
    • Panu Oksanen, MD, PhD · Sub investigator
    • Heidi Falk, MD · Sub investigator
  • New Children's Hospital
    Helsinki, 00029, Finland
    Recruiting
    • Anna-Kaisa Tuomaala, MD, PhD · Contactanna-kaisa.tuomaala@hus.fi · +358505430180
    • Tero Varimo, MD, PhD · Contacttero.varimo@hus.fi · +358445573392
    • Tero Varimo, MD,PhD · Sub investigator
    • Anne-Kaisa Tuomaala, MD,PhD · Principal investigator
    • Mari-Anne Pulkkinen, MD, PhD · Sub investigator
    • Panu Oksanen, MD · Sub investigator
    • Heidi Falk, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data will not be made publicly available. De-identified data may be shared upon reasonable request to the principal investigator, subject to applicable EU and Finnish data protection legislation and institutional approvals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Apr 2026 → Aug 2026 and primary completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 20, 2026
StartActual
Aug 15, 2026was Apr 2026
Primary completionEst.
Dec 30, 2027was Sep 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Jorvi Hospital · Espoo, Finlandno status→Recruiting
  • New Children's Hospital · Helsinki, Finlandno status→Recruiting
Oct 14, 2026
Start date
Apr 1, 2026→Aug 15, 2026 (actual)
Oct 14, 2026
Primary completion
Sep 30, 2027→Dec 30, 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Jorvi Hospital · Espoo, Finlandno status→Recruiting
    • New Children's Hospital · Helsinki, Finlandno status→Recruiting
    Start date Apr 1, 2026→Aug 15, 2026 (now actual)
    Primary completion Sep 30, 2027→Dec 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07423637
Collaborators
Insulet Corporation, Abbott Diabetes Care, NordicInfu Care AB
Responsible party
Tero Varimo, MD, PhD (MD, PhD, pediatric endocrinologist, Helsinki University Central Hospital) — Principal investigator
First posted
Feb 20, 2026
Start date
Aug 15, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Anna-Kaisa Tuomaala, MD, PhD
Contact
anna-kaisa.tuomaala@hus.fi
+358505430180
Tero Varimo, MD, PhD
Contact
tero.varimo@hus.fi
+358445573392
Anna-Kaisa Tuomaala, MD, PhD
study director · Helsinki University Central Hospital
Tero Varimo, MD, PhD
principal investigator · Helsinki University Central Hospital
Mari-Anne Pulkkinen, MD, PhD
study chair · Helsinki University Central Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion